Characterization of secretory intestinal transport of the lactone form of CPT-11

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00280-005-0042-3PMID 16003561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2

  2005cited by this paper
• Characterization of secretory intestinal transport of phenolsulfonphthalein.

  2005cited by this paper
• Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine

  2004cited by this paper
• Biliary excretion of irinotecan and its metabolites.

  2004cited by this paper
• Effect of P-Glycoprotein Modulator, Cyclosporin A, on the Gastrointestinal Excretion of Irinotecan and Its Metabolite SN-38 in Rats

  2003cited by this paper
• Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation.

  2003cited by this paper
• Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3

  2001influential reference
• Excretion Into Gastrointestinal Tract of Irinotecan Lactone and Carboxylate Forms and Their Pharmacodynamics in Rodents

  2001cited by this paper
• Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.

  2000influential reference
• Potent inhibition of the aortic smooth muscle maxi-K channel by clinical doses of ethanol.

  2000cited by this paper
• Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.

  2000cited by this paper
• ATP-dependent transport of reduced glutathione in yeast secretory vesicles.

  1998cited by this paper
• A multidrug resistance transporter from human MCF-7 breast cancer cells.

  1998cited by this paper
• Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.

  1997cited by this paper
• Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.

  1996influential reference
• Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

  1994cited by this paper
• Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

  1994cited by this paper
• Kinetic Studies of the Hydrolysis and Lactonization of Camptothecin and Its Derivatives, CPT-11 and SN-38, in Aqueous Solution

  1994cited by this paper
• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

  1993cited by this paper
• The current status of camptothecin analogues as antitumor agents.

  1993cited by this paper
• Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.

  1993influential reference
• Production of SN-38, a Main Metabolite of the Camptothecin Derivative CPT-11, and Its Species and Tissue Specificities.

  1991cited by this paper
• Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.

  1991influential reference
• In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

  1991cited by this paper
• Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.

  1980cited by this paper

• Nanoparticles from Gantrez-based conjugates for the oral delivery of camptothecin

  2021cites this paper
• Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea.

  2019cites this paper
• Role of Bacterial Translocation in the Progressive and Delayed Irinotecan Induced Diarrhea.

  2018cites this paper
• Liquid Chromatographic Method for Irinotecan Estimation: Screening of P-gp Modulators

  2015cites this paper
• Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats

  2013cites this paper
• Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11).

  2010cites this paper
• 術前補助化学療法としてS-1/paclitaxel併用療法を施行しpathological CRが得られた進行胃癌の2例

  2009cites this paper
• Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.

  2009cites this paper
• Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.

  2008cites this paper
• SECONDARY LEUKEMIA INDUCED BY HEPATIC ARTERIAL INFUSION CHEMOTHERAPY FOR MULTIPLE LIVER METASTASES OF COMMON BILE DUCT CARCINOMA AFTER PYLORUS-PRESERVING PANCREATICODUODENECTOMY-REPORT OF A CASE-

  2007cites this paper
• Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition

  2006cites this paper